J&J: encouraging results in bladder cancer
(CercleFinance.com) - J&J announces that at the weekend the Janssen pharmaceutical companies (part of the Johnson & Johnson group) presented data from a Phase 2b study evaluating the efficacy and safety of TAR-200 monotherapy in patients with high-risk, non-invasive bladder cancer (HR-NMIBC) who were unresponsive to (or ineligible for) Bacille Calmette-Guérin (BCG) therapy, or who refused radical cystectomy.
Results showed that 77% of patients achieved a complete response (CR).
TAR-200 is an investigational intra-vesical drug delivery system designed to ensure sustained local release of gemcitabine in the bladder.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Results showed that 77% of patients achieved a complete response (CR).
TAR-200 is an investigational intra-vesical drug delivery system designed to ensure sustained local release of gemcitabine in the bladder.
Copyright (c) 2023 CercleFinance.com. All rights reserved.